202 related articles for article (PubMed ID: 20586711)
1. Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer.
Kotsakis A; Georgoulias V
Expert Opin Pharmacother; 2010 Oct; 11(14):2363-89. PubMed ID: 20586711
[TBL] [Abstract][Full Text] [Related]
2. First-line treatment for advanced nonsmall cell lung cancer harboring activating epidermal growth factor receptor mutation: epidermal growth factor receptor tyrosine kinase inhibitors or chemotherapy?
Gridelli C
Curr Opin Oncol; 2011 Mar; 23(2):131-2. PubMed ID: 21307676
[No Abstract] [Full Text] [Related]
3. Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go.
Patel JD; Pasche B; Argiris A
Crit Rev Oncol Hematol; 2004 Jun; 50(3):175-86. PubMed ID: 15182824
[TBL] [Abstract][Full Text] [Related]
4. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Jänne PA; Johnson BE
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
[TBL] [Abstract][Full Text] [Related]
5. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.
John T; Liu G; Tsao MS
Oncogene; 2009 Aug; 28 Suppl 1():S14-23. PubMed ID: 19680292
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor mutations detected by denaturing high-performance liquid chromatography in nonsmall cell lung cancer: impact on response to therapy with epidermal growth factor receptor-tyrosine kinase inhibitors.
Cohen V; Agulnik JS; Ang C; Kasymjanova G; Batist G; Small D; Brandao G; Chong G; Miller WH
Cancer; 2010 Sep; 116(18):4309-17. PubMed ID: 20549828
[TBL] [Abstract][Full Text] [Related]
7. Personalized medicine for non-small-cell lung cancer.
Mok TS; Zhou Q; Leung L; Loong HH
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1601-11. PubMed ID: 20942631
[TBL] [Abstract][Full Text] [Related]
8. Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer--a review of the literature.
Araújo A; Ribeiro R; Azevedo I; Coelho A; Soares M; Sousa B; Pinto D; Lopes C; Medeiros R; Scagliotti GV
Oncologist; 2007 Feb; 12(2):201-10. PubMed ID: 17296816
[TBL] [Abstract][Full Text] [Related]
9. Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors.
Bonomi PD; Buckingham L; Coon J
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4606-12. PubMed ID: 17671150
[TBL] [Abstract][Full Text] [Related]
10. Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors.
Wong KK
Lung Cancer; 2008 Jun; 60 Suppl 2():S10-8. PubMed ID: 18513579
[TBL] [Abstract][Full Text] [Related]
11. EGFR gene status in cytological samples of nonsmall cell lung carcinoma: controversies and opportunities.
da Cunha Santos G; Saieg MA; Geddie W; Leighl N
Cancer Cytopathol; 2011 Apr; 119(2):80-91. PubMed ID: 21400669
[TBL] [Abstract][Full Text] [Related]
12. Impact of serum hepatocyte growth factor on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small cell lung adenocarcinoma.
Kasahara K; Arao T; Sakai K; Matsumoto K; Sakai A; Kimura H; Sone T; Horiike A; Nishio M; Ohira T; Ikeda N; Yamanaka T; Saijo N; Nishio K
Clin Cancer Res; 2010 Sep; 16(18):4616-24. PubMed ID: 20679350
[TBL] [Abstract][Full Text] [Related]
13. Relevance of epidermal growth factor receptor genomic gain in predicting clinical response to kinase inhibitors in non-small-cell lung cancer.
Reddy GK
Clin Lung Cancer; 2005 Nov; 7(3):163-5. PubMed ID: 16354309
[No Abstract] [Full Text] [Related]
14. Individualizing therapy for non-small-cell lung cancer: a paradigm shift from empiric to integrated decision-making.
Gandara DR; Lara PN; Mack P; Scagliotti G
Clin Lung Cancer; 2009 May; 10(3):148-50. PubMed ID: 19443333
[No Abstract] [Full Text] [Related]
15. Epidermal growth factor receptor mutations and tyrosine kinase inhibitor therapy in advanced non-small-cell lung cancer.
Technol Eval Cent Assess Program Exec Summ; 2011 Mar; 25(6):1-5. PubMed ID: 21638942
[No Abstract] [Full Text] [Related]
16. Epidermal growth factor receptor mutations and tyrosine kinase inhibitor therapy in advanced non-small-cell lung cancer.
Technol Eval Cent Assess Program Exec Summ; 2007 Nov; 22(6):1-3. PubMed ID: 18080406
[No Abstract] [Full Text] [Related]
17. Epidermal growth factor receptor (EGFR) signaling and covalent EGFR inhibition in lung cancer.
Heuckmann JM; Rauh D; Thomas RK
J Clin Oncol; 2012 Sep; 30(27):3417-20. PubMed ID: 22915655
[No Abstract] [Full Text] [Related]
18. Targeting EGFR mutation in non-small-cell lung cancer: challenges and future perspectives.
Haddad FG; Kourie HR; Kattan J
Future Oncol; 2017 Feb; 13(3):201-204. PubMed ID: 27624407
[No Abstract] [Full Text] [Related]
19. Using EGFR status to personalize treatment: lung cancer researchers reach a milestone.
Friedrich MJ
J Natl Cancer Inst; 2009 Aug; 101(15):1039-41. PubMed ID: 19638503
[No Abstract] [Full Text] [Related]
20. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brain.
Jamal-Hanjani M; Spicer J
Clin Cancer Res; 2012 Feb; 18(4):938-44. PubMed ID: 22167408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
